What Is BPC 157? The Gastric Peptide Behind the Research

What is BPC 157 and where did it come from?

BPC stands for body protection compound. The Zagreb group, working at the University of Zagreb medical school, isolated a protective protein fraction from human gastric juice and went on to synthesise a 15 amino acid section of it, numbered 157. The result is a pentadecapeptide that does not occur on its own in nature: it is a lab-made fragment, which is why it is called synthetic.

It has picked up other names along the way. Pharmaceutical development under the Croatian company Pliva used the codes PL 14736, PL-10 and PLD-116, and it is sometimes called bepecin. Research suppliers simply sell it as BPC-157 or BPC 157.

Sequence and structure

In one-letter code the sequence reads GEPPPGKPADDAGLV: fifteen residues with a molecular weight of about 1419 Da. That run of three prolines near the start gives the chain an unusually rigid shape, and it is part of the reason the Zagreb papers describe BPC-157 as a "stable gastric pentadecapeptide": it resists breakdown in gastric juice for far longer than most peptides.

That stability is the practical property that sets it apart. It is why BPC-157 is one of very few peptides studied in oral form as well as in solution, and why it is sold in capsules at all.

What does BPC 157 do? The research areas

No human mechanism has been established, so "what does BPC 157 do" is best answered as "what has it done in models". Four threads run through the literature:

• Tendon and ligament. Staresinic and colleagues (Journal of Orthopaedic Research, 2003) reported faster, stronger healing of transected Achilles tendons in rats, with a higher load to failure. Chang et al. (Journal of Applied Physiology, 2011) found it increased outgrowth, survival and migration of tendon fibroblasts through the FAK and paxillin pathway, without directly increasing proliferation.
• Gut. The original line of work: gastric ulcer, inflammatory bowel and fistula models, which led to the PL 14736 ulcerative colitis programme.
• Nitric oxide system. Many Zagreb papers describe BPC-157 as modulating nitric oxide signalling, protecting the endothelium that lines blood vessels.
• VEGF and angiogenesis. Hsieh et al. (Journal of Molecular Medicine, 2017) reported raised VEGFR2 expression and Akt-eNOS activation in endothelial cells, a plausible route to new blood vessel growth in injured tissue.

You can read the papers themselves, with PubMed links, in our BPC-157 citation library.

BPC 157 benefits: what the evidence does and does not support

The reported BPC 157 benefits are real findings in rodents: better tendon biomechanics, faster ulcer and fistula closure, protection of blood vessel lining. The 2025 HSS Journal systematic review by Vasireddi and colleagues summarised it fairly: promising preclinical results in muscle, tendon, ligament and bone injury, but only level IV and V evidence, and no clinical safety data.

In people, the evidence is three small reports from one clinician: a 2021 knee pain chart review of 16 patients, a 2024 interstitial cystitis series of 12, and a 2025 intravenous safety pilot in two healthy adults. None had a placebo group. Our opinion, for what it is worth: BPC-157 is one of the most interesting peptides in tissue repair research precisely because the animal data are so consistent, and one of the most oversold because that consistency has never been tested in a proper trial. Side effects are covered in our BPC-157 side effects evidence review.

Does BPC 157 work, and how long does it take?

Does BPC 157 work? In rat models, repeatedly, yes, by the measures those studies chose. In humans the question is simply unanswered, because nobody has run the trial that could answer it.

The same applies to timing. In animal models, outcomes are usually measured over days to a few weeks after an induced injury, which reflects the healing window of a rat rather than a person. In the 2021 knee chart review, patients were looked at six months to a year after treatment, but without controls that says nothing reliable about onset. There is no evidence-based answer to how long BPC-157 takes to work in people.

Vial or capsules

AminoBlend supplies BPC-157 in two formats, and the choice follows the research design:

The vial is reconstituted with bacteriostatic water for peptide vials; the BPC-157 concentration calculator works out the strength per mL for the volume you add. Many labs also pair it with TB-500, and our BPC-157 and TB-500 comparison explains the difference between the two.

Shop BPC 157 Online: Vial, Capsules or the Wolverine Blend

Most labs buy the BPC-157 10 mg vial at $69, because powder lets you set the working concentration yourself. The 60-capsule bottle ($79, 500 mcg per capsule) is the one to buy for oral-format study designs. If your work pairs it with TB-500, we recommend separate vials of each so either compound can be tracked on its own; the Wolverine Blend at $69 suits designs that only ever test the two together, and it comes in $5 under the price of half a BPC-157 vial plus half a TB-500 vial. Shop online from Australian stock, add bacteriostatic water for the vial, and check the lot certificate before you order.

Research use only

BPC-157 is not an approved medicine in Australia and is not on the ARTG. AminoBlend offers it to laboratories for research alone; it is not for people or animals, and we give no dosing advice. See our research use only terms, and for the regulatory detail read where BPC-157 stands under Australian law. The full tissue repair research catalogue includes TB-500, the Wolverine blend and KLOW.